Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ondansetron: a novel antiemetic agent.
Figg WD, Graham CL, Hak LJ, Dukes GE. Figg WD, et al. South Med J. 1993 May;86(5):497-502. South Med J. 1993. PMID: 8488393 Review.
Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. Figg WD, et al. J Clin Pharmacol. 1996 Mar;36(3):206-15. doi: 10.1002/j.1552-4604.1996.tb04190.x. J Clin Pharmacol. 1996. PMID: 8690814 Clinical Trial.
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Abel ML, Takahashi N, Peer C, Redon CE, Nichols S, Vilimas R, Lee MJ, Lee S, Shelat M, Kattappuram R, Sciuto L, Pinkiert D, Graham C, Butcher D, Karim B, Sharma AK, Malin J, Kumar R, Schultz CW, Goyal S, Del Rivero J, Krishnamurthy M, Upadhyay D, Schroeder B, Sissung T, Tyagi M, Kim J, Pommier Y, Aladjem M, Raffeld M, Figg WD, Trepel J, Xi L, Desai P, Thomas A. Abel ML, et al. Among authors: figg wd. Clin Cancer Res. 2023 Sep 15;29(18):3603-3611. doi: 10.1158/1078-0432.CCR-23-0536. Clin Cancer Res. 2023. PMID: 37227187 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 37154821
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Sausville EA, et al. Among authors: figg wd. J Clin Oncol. 2001 Apr 15;19(8):2319-33. doi: 10.1200/JCO.2001.19.8.2319. J Clin Oncol. 2001. PMID: 11304786 Clinical Trial.
Dose Optimization of Pembrolizumab: Less May Be More.
Ratain MJ, Peer CJ, Figg WD, Goldstein DA. Ratain MJ, et al. Among authors: figg wd. Clin Pharmacol Ther. 2022 May;111(5):993. doi: 10.1002/cpt.2490. Epub 2021 Dec 1. Clin Pharmacol Ther. 2022. PMID: 34854077 No abstract available.
793 results